Skip to main content
News

NIH Partnership to Advance New Parkinson Treatments


February 07, 2018

Part of the National Institutes of Health (NIH) Accelerating Medicines Partnership (AMP), the NIH will now also be focusing on identifying promising biomarkers in Parkinson disease (PD) in order to develop new targeted therapies, according to an NIH press release (January 30, 2018).

The AMP, launched in February 2014, is a public-private partnership between the NIH, the Food and Drug Administration (FDA), 12 biopharmaceutical and life science companies, and 13 non-profit organizations with the aim of transforming the current model for developing new diagnostics and treatments through the identification of biological targets for therapies.

As of January 2018, the AMP project on PD was launched with 9 partners. “Advancing treatments for Parkinson’s disease is hampered by insufficient understanding of biological networks; drugs aimed at seemingly promising therapeutic targets fail in clinical trials,” said NIH Director Francis S Collins, MD, PhD. “By combining our expertise and resources, AMP PD partners hope to increase our collective odds of success in accelerating the development of effective treatments for a million Americans who suffer from this debilitating disease.”

AMP PD partners include Celgene, Summit, New Jersey; GlaxoSmithKline, Philadelphia; The Michael J. Fox Foundation for Parkinson’s Research (MJFF), New York; Pfizer, New York; Sanofi, Bridgewater, New Jersey; and Verily, South San Francisco, California. These organizations will invest a combined total of $12 million over 5 years through the Foundation for the National Institutes of Health, which will manage the project. This total includes $2 million of in-kind contributions in software and services from Verily.

NIH’s National Institute of Neurological Disorders and Stroke (NINDS) will match the private sector funds with an additional $12 million contribution, pending availability of funds. The FDA will also be a critical partner in providing regulatory guidance.

“There is a wealth of biosamples and data already collected by NIH and MJFF from people with Parkinson’s disease,” said NINDS Director Walter Koroshetz, MD. “Sharing resources from public-private partnerships to generate and analyze ‘big data’ made available through AMP may be our greatest opportunity for accelerating the pace of discovery for translation into more effective treatments for PD.”

—Amanda Del Signore


For more articles like this, visit the Parkinson Disease Resource Center

For more Annals of Long-Term Care articles, visit the homepage

To view the Annals of Long-Term Care print issue, click here

Back to Top